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An  open-labeled  randomized  study  was  conducted  to compare  the  immunogenicity  and  safety  of  polysac-
charide  (PPV23)  or protein-conjugated  pneumococcal  vaccine  (PCV7)  among  the  elderly  aged  80  years
or older.  A  total  of  105 nursing  home  residents  were  enrolled  in  this  study.  We  analyzed  the  geometric
mean  concentration  (GMC)  of  serotype-speciﬁc  immunoglobulin  G (IgG)  and  the  geometric  mean  titer
(GMT)  of  the  opsonization  index  (OI)  for serotypes  4, 6B,  9V,  14, 18C,  19F,  and  23F.  The  GMCs  of  serotype-
speciﬁc  IgG  and  the GMTs  of  the OI signiﬁcantly  increased  one  month  after  vaccination  in  both  groups
for  all  seven  serotypes  evaluated.  In the  PCV7  group,  study  subjects  with  serotypes  4, 9V,  18C,  and  23F
exhibited  statistically  signiﬁcant  elevations  in both  serotype-speciﬁc  IgGs  and  OIs  compared  to those  of
the PPV23  group.  Both  vaccines  were  tolerated  without  any  severe  adverse  events,  and  no  differencesneumococcal protein-conjugate vaccine
neumococcal polysaccharide vaccine
lderly patients
in  systemic  adverse  events  were  observed  between  the  two  groups,  although  adverse  reactions  such  as
redness  and localized  swelling  were  more  common  in  the  PCV7  group.  Our  data  demonstrated  that  the
GMCs of  serotype-speciﬁc  IgG and  the  GMTs  of the  OI were  higher  in  the  PCV7  group  compared  to those
in  the  PPV23  group.  Our  study  also  conﬁrmed  the  safety  of  both  the PCV7  and PPV23  vaccines  in  elderly
people  aged  80  years  or older.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Streptococcus pneumoniae infection is a major cause of mortality
nd morbidity worldwide among the elderly. The 23-valent pneu-
ococcal polysaccharide vaccine (PPV23) is widely recommendedor administration to those who are at a high risk of S. pneumo-
iae infection, such as elderly people and splenectomy patients [1].
owever, owing to the puriﬁed free polysaccharides that comprise
∗ Corresponding author at: Center for Infectious Diseases and Infection Control,
eio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582,
apan. Tel.: +81 3 3353 3793; fax: +81 3 3353 2502.
E-mail address: n-hasegawa@z8.keio.jp (N. Hasegawa).
ttp://dx.doi.org/10.1016/j.vaccine.2014.11.023
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
its surface capsule, PPV23 does not elicit T cell-dependent immune
responses and is a poor inducer of immunologic memory. Fur-
thermore, vaccine-induced antibody titers may achieve insufﬁcient
levels and decrease annually, particularly 5 years after vaccination
[2].
The conjugation of the capsular polysaccharide to a diphtheria
protein stimulates not only B-cell immune response but also T cell-
dependent immune responses and enhanced memory response at
the time of boosting [3]. Therefore, pneumococcal conjugate vac-
cines produce superior immune responses, particularly in infants.
For this reason, the heptavalent pneumococcal conjugate vaccine
(PCV7) was  licensed in 2000 in the United States and in 2009 in
Japan. PCV7 also produces better immune responses than PPV23 in
groups at higher risk of developing invasive pneumococcal diseases
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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nd pneumococcal pneumonia, such as individuals with HIV [4] or
hronic obstructive pulmonary disease [5].
In healthy elderly people 50–80 years old, Goldblatt et al. [6]
eported that PCV7 produced superior immunogenicity compared
ith PPV23. In recent years, the increasing number of elderly peo-
le over 80 years old hospitalized for pneumococcal pneumonia has
een reported [7]. While pneumococcal vaccination is strongly rec-
mmended for this population, no data are currently available for
omparison of the immunogenicity and safety between PCV7 and
PV23 for this age group. Therefore, we performed this prospective
tudy to clarify these unknown aspects.
. Materials and methods
.1. Study subjects
The present study was a randomized, open-label study designed
o compare the immunogenicity and safety of PCV7 (Prevenar;
ﬁzer) with those of PPV23 (Pneumovax; MSD). Data were col-
ected between April 2011 and December 2012 from participants
ho were 80 years or older and had never received pneumococcal
accinations. None of the participants had any documented history
f pneumococcal infection. They were selected from ﬁve differ-
nt nursing homes around Tokyo and were randomly assigned to
ither the PPV23 group or the PCV7 group using the sealed enve-
ope system with a 1:1 allocation ratio. A total of 105 participants
ere enrolled in this study, and all participants provided written
nformed consent.
In addition, subjects were excluded if they had a history of
ny streptococcal vaccination, a history of anaphylactic reaction to
iphtheria toxin, or symptoms of fever on the day of vaccination.
We set the sample size on the basis of a study by Goldblatt
t al. [6] on the comparison of immunogenicity between PCV7 and
PV23 among adults aged 50–80 years. They assigned 33–60 sub-
ects to a subgroup of one arm and showed higher geometric mean
oncentrations (GMCs) of serotype-speciﬁc IgG response in several
erotypes.
This study was reviewed and approved by the Research Ethics
ommittee of Keio University School of Medicine (2010-231-2) and
y the Research Ethics Committee of Kitasato University Kitasato
nstitute Hospital (1108-02). This trial was registered with the
MIN Clinical Trials Registry (UMIN000006132).
.2. Vaccines
The PCV7 used in this study is currently licensed only for pedi-
tric use in Japan. PCV7 contains polysaccharides of pneumococcal
erotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, which are conjugated to
he protein carrier CRM197, a nontoxic variant of the diphtheria
oxin. Each serotype-speciﬁc polysaccharide is conjugated sepa-
ately prior to formulation as a multivalent vaccine. The vaccine
ontains aluminum phosphate as an adjuvant.
PPV23 contains a mixture of puriﬁed capsular polysaccharides
rom 23 different serotypes of S. pneumoniae: 1, 2, 3, 4, 5, 6B, 7F, 8,
N, 9V, 10, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and
3F. This vaccine is adjuvant-free.
Each participant received 0.5 mL  of either PPV23 or PCV7 via
ubcutaneous injection. PPV23 and PCV7 were dispensed and
dministered by members who were not blinded and not involved
n subsequent data analysis..3. Samples
Blood samples (10 mL)  were drawn from all the subjects on the
ay of vaccination and approximately one month after vaccination.e 33 (2015) 327–332
Sera were separated by centrifugation (3500 rpm, 15 min, 4 ◦C) and
stored at −80 ◦C.
2.4. Enzyme-linked immunosorbent assay (ELISA)
Anti-pneumococcal immunoglobulin G (IgG) antibodies were
measured by World Health Organization (WHO)-approved ELISA,
using standard reference serum (89-SF or 007sp) and C-
polysaccharide and 22F polysaccharide absorption, as previously
reported [8,9]. The levels of serotype-speciﬁc IgGs for seven
serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) were determined in
both vaccination groups according to the WHO  protocol (a detailed
version of the protocol is available at http://www.vaccine.uab.edu/
ELISAProtocol(89SF).pdf). These serotypes are covered by PCV7.
2.5. Multiplexed opsonophagocytic killing assay
A multiplexed opsonophagocytic killing assay for seven
serotypes, 4, 6B, 9V, 14, 18C, 19F, and 23F, based on antibiotic-
resistant strain target bacteria, was performed at the Research
Institute for Microbial Diseases, Osaka University, as previously
described [10]. The quality control serum used in each assay
was prepared from the pooled sera of adults vaccinated with
PPV23 or PCV7. The opsonization index (OI) was deﬁned as the
serum dilution capable of killing 50% of the bacteria, which
was determined by using opsotiter3 software according to the
WHO  protocol (a detailed version of this protocol is available at
www.vaccine.uab.edu/UAB-MOPA.pdf) [11]. Laboratory analysis,
ELISA, and a multiplexed opsonophagocytic killing assay were per-
formed by members who  were blinded to vaccine allocation.
2.6. Adverse reactions
All patients were observed daily by medical staff to monitor
body temperature and any local or systemic reactions, starting from
the day of vaccination to day 7. Injections were graded based on
the occurrence of several possible adverse events as follows: grade
I (the reaction was present but easily tolerated), grade II (the reac-
tion interfered with normal activity), and grade III (the reaction was
severe or incapacitating).
2.7. Statistical analysis
Average antibody concentrations and the increases from base-
line were expressed as geometric means. Differences in the GMCs of
serotype-speciﬁc IgG and the geometric mean titers (GMTs) of the
OI were assessed by the Wilcoxon matched-pairs signed-ranks test.
For multiple comparisons, we  calculated Bonferroni-adjusted P val-
ues. The frequencies of adverse reactions were compared between
vaccinations by the Fisher exact test. Differences with P < 0.05 were
considered to be statistically signiﬁcant. Data analysis was per-
formed by members who  were blinded to vaccine allocation.
3. Results
3.1. Participant characteristics
Overall, 623 eligible participants were reviewed in the 5 nursing
homes (Fig. 1). One hundred and ﬁve participants were enrolled
in this study after they provided written informed consent. Five
subjects were subsequently dropped from the study prior to vac-
cination (2 subjects were hospitalized, 2 subjects left the nursing
home, and 1 subject died). Consequently, 100 subjects were vac-
cinated (Table 1); of these, 49 received PPV23 and 51 received
PCV7. The mean ages at enrollment were 88.3 years for the PPV23
group and 87.7 years for the PCV7 group, with 45 subjects in their
H. Namkoong et al. / Vaccin
Table  1
Participants characteristics.
Characteristics PPV23a
(n = 49)
PCV7b
(n = 51)
P value
Age, years 88.3 ± 1.4 87.7 ± 1.5 0.29
Male, % 12 (24.5) 11 (21.6)
Female, % 37 (75.5) 40 (78.4)
Height, cm 145.1 ± 3.9 146.5 ± 2.2 0.24
Weight, kg 45.9 ± 2.4 46.0 ± 2.1 0.47
Hypertension, % 34 (69.4) 32 (62.7)
Diabetes mellitus, % 15 (30.6) 18 (35.2)
Old cerebral infarction, % 17 (34.7) 14 (27.5)
Dementia, % 15 (30.6) 13 (25.5)
Dyslipidemia, % 14 (28.6) 12 (23.5)
Neck of femur fracture, % 12 (24.5) 13 (25.5)
Congestive heart failure, % 12 (24.5) 10 (19.6)
Vertebral compression
fracture, %
11 (22.4) 9 (17.6)
Cataract, % 6 (12.2) 5 (9.8)
Chronic obstructive
pulmonary disease, %
6 (12.2) 3 (5.9)
Old myocardial infarction,
%
5 (10.2) 5 (9.8)
Malignancy, % 4 (8.1) 5 (9.8)
Benign prostatic
hyperplasia, %
5 (10.2) 3 (5.9)
White blood cells,
counts/l
5796 ± 398 6101 ± 431 0.15
Hemoglobin, g/dl 11.8 ± 0.4 12.2 ± 0.4 0.09
Platelets, ×104 counts/l 23.6 ± 2.2 22.8 ± 2.0 0.28
Albumin, g/dl 3.7 ± 0.1 3.7 ± 0.1 0.35
AST,  IU/l 20.7 ± 2.0 21.1 ± 2.9 0.40
ALT,  IU/l 12.9 ± 2.0 13.5 ± 2.5 0.35
BUN, mg/dl 17.6 ± 1.0 16.5 ± 1.3 0.10
Creatinine, mg/dl 0.68 ± 0.5 0.70 ± 0.5 0.25
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a 23-valent pneumococcal polysaccharide vaccine.
b 7-valent pneumococcal conjugate vaccine.
0s and 3 subjects who  were 101 years old. The majority (77%)
f the subjects were female. There were no signiﬁcant differences
n major co-morbidities between the PPV23 group and the PCV7
roup. No other signiﬁcant differences in laboratory data were
bserved between the two groups. All the participants from both
roups received routine immunization against seasonal inﬂuenza.
.2. Immunogenicity: levels of serotype-speciﬁc IgG
Data for the GMCs of serotype-speciﬁc IgG responses before
nd one month after vaccination with PPV23 or PCV7 are summa-
ized in Table 2 and presented graphically in Fig. 2. The original
ata on serotype-speciﬁc IgG are also shown in Supplementary
able 1. No signiﬁcant differences of baseline serotype-speciﬁc IgG
MCs were observed between the two groups for all serotypes
easured. In both groups, signiﬁcant increases in IgG GMCs were
bserved from baseline to one month following the initial dose
or all seven serotypes evaluated. The GMCs of serotype-speciﬁc
gGs for serotypes 4, 9V, 18C, and 23F of the study subjects were
igniﬁcantly more elevated in the PCV7 group than in the PPV23
roup.
.3. Immunogenicity: OI
Data for the GMTs of serotype-speciﬁc OIs before and one
onth after vaccination with PPV23 or PCV7 are summarized in
able 3 and presented graphically in Fig. 3. The original data on
erotype-speciﬁc OIs are also shown in Supplementary Table 2. No
igniﬁcant differences in the baseline GMTs of serotype-speciﬁc
Is were observed between the two groups for all serotypes mea-
ured. In both groups, signiﬁcant increases in the GMTs of OIs were
bserved from baseline to one month following the initial dosee 33 (2015) 327–332 329
for all seven serotypes evaluated. The GMTs of serotype-speciﬁc
OIs for serotypes 4, 9V, 18C, and 23F of the study subjects were
signiﬁcantly elevated in the PCV7 group compared to the PPV23
group.
3.4. Safety
Both vaccines were tolerated without any severe adverse events.
No differences were observed in systemic side effects between the
two groups; however, local side effects such as redness and local-
ized swelling were more commonly observed in the PCV7 group
(Table 4). No participants required unscheduled medical examina-
tions within the ﬁrst 7 days after vaccination.
4. Discussion
The current study is the ﬁrst to demonstrate pneumococcal vac-
cine responses in pneumococcus vaccine-naïve elderly people (at
or over 80 years of age) by evaluating serotype-speciﬁc IgG anti-
bodies and serotype-speciﬁc OIs between PPV23 and PCV7. Our
major ﬁndings are that both PPV23 and PCV7 elicited increases in
IgG and OI, and that PCV7 is more potent than PPV23 in terms of
its immunogenicity against four out of seven serotypes included
in PCV7. We  also demonstrated the safety of these preparations in
these elderly individuals, with no serious adverse effects observed
in either group.
We  believe that there are several important strengths of this
study. One of them is that not only serotype-speciﬁc IgG levels but
also serotype-speciﬁc OIs were evaluated. Due to technical difﬁcul-
ties with OI assays, OI measurements have been reported in only
a limited number of clinical studies to date. However, we were
able to evaluate functional antibodies, which are superior surro-
gate markers for protection against pneumococcal pneumonia and
bacteremia, by utilizing the latest generation of ELISA methodology
[12].
Another important strength of this study is the age distribu-
tion of the participants, considering the current inevitable tendency
toward increasing longevity in humans. Since the host response
induced by vaccinations varies depending on the age of the recip-
ient, the development of safe and effective vaccinations for the
elderly is clinically important.
In our study, antibodies against serotypes 4, 9V, 18C, and
23F were signiﬁcantly elevated in the study subjects. These
data were consistent with a previous study indicating that
serotype-speciﬁc IgG levels of 4, 6B, 9V, 14, 18C, and 23F, and
serotype-speciﬁc OIs of 4, 9V, 14, 18C, and 23F were signiﬁcantly
elevated in the PCV7 group consisting of elderly people more
than 70 years old [2]. In addition, in accordance with our data,
they reported that serotype 6B and 19F did not show superior
immunogenicity compared with other serotypes in elderly peo-
ple.
In several studies, 1.0-mL doses of PCV7 were administered
[5,13]. However, we  used half this dosage in our clinical study
to minimize potential adverse effects. In fact, both PPV23 and
PCV7 were tolerated by the participants and were associated with
few local reactions or systemic adverse effects. No severe adverse
effects were observed in either group. A higher frequency of local
reactions was observed in the PCV7 group compared with the
PPV23 group, although we  were unable to determine if this increase
was caused by the conjugation speciﬁcally. According to a dose-
range study of pneumococcal conjugate vaccine reported by Lode
et al. [14], both serotype-speciﬁc IgG and OI displayed increases
in dose-dependent manners, although local reactions for the dou-
ble dose were not statistically higher than for the single dose.
Based on this notion, in our study, 1.0-mL injections rather than
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Assessed for eli gibility (n=623) 
Excluded (n=518) 
Not meeting incl usion criteria (n= 365) 
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.5-mL injections of PCV7 could have safely obtained more potent
mmunogenicity.
The mean number of co-morbidities of study participants stay-
ng at nursing homes was 3.34 in our study. According to the
ationwide epidemiological study in Scotland by Barnett K et al.,
he mean number of co-morbidities is 2.60 in elderly people aged
5–84 years and 3.62 in elderly people aged 85 and over [15]. The
ross sectional study of aged Medicare beneﬁciaries in the United
tates shows that the mean number of co-morbidities is 2.71 in
lderly people aged 80 and over [16]. Considering these previous
ata, our study population of nursing homes could be regarded as
ot an unusual population of the elderly people in the developed
ountries.
able 2
he geometric mean concentrations of serotype-speciﬁc IgG antibody before and one mo
Serotype Pre IgG g/ml (95% CI) Post Ig
PPV23a (n = 49) PCV7b (n = 51) PPV23
4* 0.44 (0.35–0.55) 0.52 (0.42–0.66) 1.02 (0
6B  1.22 (1.00–1.64) 1.11 (0.84–1.39) 3.51 (2
9V* 1.03 (0.81–1.38) 0.92 (0.70–1.18) 4.01 (3
14  1.88 (1.44–2.85) 2.26 (1.61–3.22) 7.66 (5
18C* 1.12 (0.89–1.56) 1.08 (0.80–1.39) 4.93 (3
19F  1.69 (1.38–2.15) 2.24 (1.72–2.82) 5.26 (3
23F* 1.28 (0.95–1.81) 1.31 (0.95–1.80) 5.39 (3
a 23-valent pneumococcal polysaccharide vaccine.
b 7-valent pneumococcal conjugate vaccine.
* A signiﬁcant difference in absolute postvaccination IgG levels between vaccine group
ithin each study group, postvaccination antibody levels were higher than baseline (P < am of trial.
This study has several limitations. Firstly, a vaccine type and
an injection route have to be considered. In this study, we
could not use PCV13 because of the lack of the license in Japan
at the time of the current study, while PCV13 was launched
in Japan in 2014. Therefore our study is out-of-date data at
the present. Although PCV is usually administered intramuscu-
larly, not subcutaneously, an intramuscular injection of PCV7
was not allowed in Japan at the time of our clinical study. In
order to minimize injection dependent bias, we  administered
PCV7 subcutaneously by following that the most common route
of PPV23 is the subcutaneous route in Japan. Even though, we
should have administered both PPV23 and PCV7 intramuscu-
larly.
nth after vaccination pneumococcal vaccines.
G g/ml (95% CI) Bonferroni-adjusted
P value
 (n = 49) PCV7 (n = 51)
.77–1.34) 3.38 (2.32–4.92)* >0.001
.66–5.30) 3.32 (2.08–4.84) 6.205
.12–5.66) 8.75 (5.80–12.14)* 0.003
.00–14.02) 11.41 (7.57–18.26) 3.723
.53–6.76) 10.02 (6.98–14.39)* 0.043
.65–7.30) 6.10 (4.08–8.45) 2.467
.51–8.98) 14.68 (9.75–22.04)* 0.014
s.
0.01) for all serotypes.
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Table  3
The geometric mean titers of serotype-speciﬁc opsonization index before and one month after vaccination pneumococcal vaccines.
Serotype Pre OIa (95% CI) Post OI (95% CI) Bonferroni-adjusted
P value
PPV23b (n = 49) PCV7c (n = 51) PPV23 (n = 49) PCV7 (n = 51)
4* 3.55 (2.55–5.22) 5.77 (3.53–9.44) 45.84 (25.55–104.83) 710.65* (307.45–1642.62)* 0.005
6B  17.97 (10.58–38.69) 23.34 (12.10–40.88) 271.51 (123.06–586.19) 700.27 (327.87–1188.63) 2.227
9V* 24.44 (13.77–49.77) 19.34 (9.97–34.30) 234.47 (138.37–478.25) 958.78* (559.49–1680.79)* 0.012
14  44.83 (24.67–101.30) 90.57 (38.43–183.84) 588.67 (262.75–1380.93) 1925.23 (1144.17–3430.09) 2.259
18C* 47.67 (25.48–89.65) 39.13 (19.53–69.75) 708.20 (329.96–1295.19) 2730.37* (1805.42–4118.33)* 0.016
19F  18.26 (10.23–32.94) 25.94 (13.43–45.32) 352.42 (163.69–628.10) 414.32 (196.85–707.47) 3.572
23F* 19.00 (10.50–35.76) 14.51 (7.30–26.69) 197.51 (80.78–466.58) 2076.51* (1129.01–3937.53)* >0.001
a Opsonization index.
b 23-valent pneumococcal polysaccharide vaccine.
vels b
W r all se
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sc 7-valent pneumococcal conjugate vaccine.
* Bolded items represent a signiﬁcant difference in absolute postvaccination OI le
ithin each study group, postvaccination OI were higher than baseline (P < 0.01) foAnother limitation is that it was only one month after vaccina-
ion that the antibody levels were examined, thereby limiting our
nowledge regarding long-term effects. Our recent study suggested
ustained levels of serotype-speciﬁc IgG and OI after primary and
ig. 2. The serotype-speciﬁc baseline and 1-month absolute IgG antibody levels are show
haride vaccine (PCV7) resulted in statistically signiﬁcantly higher antibody levels at one
ig. 3. The serotype-speciﬁc baseline and one-month geometric mean opsonophagocyti
neumococcal polysaccharide vaccine (PCV7) resulted in statistically signiﬁcantly high
erotypes 4, 9V, 18C and 23F.etween vaccine groups.
rotypes.secondary vaccination with PPV23 among elderly individuals with
chronic lung diseases [17]. We  therefore intend to compare the
serotype-speciﬁc IgG and OI after primary vaccination between the
study subjects immunized with PPV23 and PCV7 in this study.
n for each patient. The heptavalent diphtheria-conjugated pneumococcal polysac-
 month to baseline for serotypes 4, 9V, 18C and 23F.
c killing index are shown for each patient. The heptavalent diphtheria-conjugated
er geometric mean opsonophagocytic killing index at one month to baseline for
332 H. Namkoong et al. / Vaccin
Table 4
Comparison of adverse reactions among elderly individuals after vaccination with
pneumococcal vaccines.
Characteristics PPV23a
(n = 49)
PCV7b
(n = 51)
P value
Fatigue
Grade I 3 3 0.96
Grade II 0 0 –
Muscle aches
Grade I 0 0 –
Grade II 0 0 –
Headache
Grade I 0 0 –
Grade II 0 0 –
Itching of vaccinated arm
Grade I 2 4 0.43
Grade II 0 0 –
Pain of vaccinated arm
Grade I 0 0 –
Grade II 0 0 –
Fever
Grade I 4 3 0.65
Grade II 0 0 –
Redness
Grade I (<8 cm) 9 16 0.13
Grade II (>8 cm and <15 cm) 3 5 0.50
Grade III (>15 cm)  0 0 –
Localized swelling
Grade I (<8 cm) 11 19 0.11
Grade II (>8 cm and <15 cm) 0 0 –
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Drug-resistant genes and serotypes of pneumococcal strains of community-a 23-valent pneumococcal polysaccharide vaccine.
b 7-valent pneumococcal conjugate vaccine.
There are several unsolved issues for pneumococcal vaccination.
he titer of correlate of protection for adults who  received pneu-
ococcal vaccines has not yet been established, while a titer of
.35 g/mL has been deﬁned as a correlate of protection against
nvasive diseases among infants who received the pneumococcal
onjugate vaccine. In this respect, as for adults, the advantage of
he higher immunogenicity in the PCV7 group is not clear in pro-
ection against pneumococcal diseases. Moreover, the difference of
he serotypes covering range by each pneumococcal vaccine has to
e taken into consideration. Based on the newest domestic reports
n the serotype distribution of community-acquired pneumonia
CAP) [18] and invasive pneumococcal disease (IPD) [19], the ratio
f serotypes of CAP covered by PPV23, PCV7 and PCV13 are 82.5%,
1.4% and 83.3% while the ratio of serotypes of IPD covered by
PV23, PCV7 and PCV13 are 85.4%, 39.8% and 61.9%, respectively.
aken together, to make best of our current study, the nation-
ide surveillance of S. pneumoniae infections is essential in Japan.
eyond the scope of this current study, the most important aspect
s to establish the vaccine policy which produce clinical efﬁcacy for
reventing S. pneumoniae infections.
In conclusion, we demonstrated higher increases in the GMCs
f serotype-speciﬁc IgG levels and the GMTs of OIs in the PCV7
roup compared to the PPV23 group, and conﬁrmed the safety of
accinations with PCV7 and PPV23 for subjects aged 80 years and
lder.
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